Delta Hepatitis in HIV Patients

[Guest guest]

http://www.medscape.com/viewarticle/580606?src=mp & spon=20 & uac=31238BR

4th International HIV and Hepatitis Co-infection Workshop

Selection from: The 4th International HIV and Hepatitis Co-infection Workshop

Conference Summary

Introduction: 4th International HIV and Hepatitis Co-infection Workshop

More than 400 hepatologists and infectious diseases specialists attended this

year's Co-infection Workshop, which was held in Madrid at the beginning of the

summer. Many of the top leaders in the field participated in the meeting and

discussed the most challenging aspects and controversies in the field of

coinfection with HIV and hepatitis viruses.

Delta Hepatitis in HIV Patients

Around 10% to 15% of chronic HBV carriers are seropositive for delta antibodies,

regardless of HIV infection. The majority of HDV-Ab+ individuals are viremic for

delta virus[42] and therefore are actively superinfected, showing a more rapid

progression of liver disease. Patients with HIV infection show higher viral load

levels of HDV than their HIV-negative patients. Heiner Wedemeyer[43] (Hannover

Medical School, Hannover, Germany) discussed the course of delta hepatitis,

stressing its epidemiology in HIV-infected individuals and the potential impact

of wide and prolonged use of anti-HBV medications in this population. Spanish

researchers showed that by sustained suppression of HBV replication,

long-lasting treatment with anti-HBV antiretroviral drugs may provide an

indirect inhibitory effect on HDV replication.[42]

Delta virus requires the replication of HBV to propagate. Little is know about

its behavior in patients harboring distinct HBV genotypes. Spanish researchers

found that the inhibitory effect of HDV on HBV is more pronounced in HBV-A than

HBV-D. A higher production of HBsAg by HBV-D could diminish the competition

between HBV and HDV for HBsAg, allowing a more efficient HBV encapsidation.[44]

The clinical impact of infection with distinct HBV genotypes in patients with

delta virus superinfection has not yet been examined and warrants further

investigation.

[Guest guest]

http://www.medscape.com/viewarticle/580606?src=mp & spon=20 & uac=31238BR

4th International HIV and Hepatitis Co-infection Workshop

Selection from: The 4th International HIV and Hepatitis Co-infection Workshop

Conference Summary

Introduction: 4th International HIV and Hepatitis Co-infection Workshop

More than 400 hepatologists and infectious diseases specialists attended this

year's Co-infection Workshop, which was held in Madrid at the beginning of the

summer. Many of the top leaders in the field participated in the meeting and

discussed the most challenging aspects and controversies in the field of

coinfection with HIV and hepatitis viruses.

Delta Hepatitis in HIV Patients

Around 10% to 15% of chronic HBV carriers are seropositive for delta antibodies,

regardless of HIV infection. The majority of HDV-Ab+ individuals are viremic for

delta virus[42] and therefore are actively superinfected, showing a more rapid

progression of liver disease. Patients with HIV infection show higher viral load

levels of HDV than their HIV-negative patients. Heiner Wedemeyer[43] (Hannover

Medical School, Hannover, Germany) discussed the course of delta hepatitis,

stressing its epidemiology in HIV-infected individuals and the potential impact

of wide and prolonged use of anti-HBV medications in this population. Spanish

researchers showed that by sustained suppression of HBV replication,

long-lasting treatment with anti-HBV antiretroviral drugs may provide an

indirect inhibitory effect on HDV replication.[42]

Delta virus requires the replication of HBV to propagate. Little is know about

its behavior in patients harboring distinct HBV genotypes. Spanish researchers

found that the inhibitory effect of HDV on HBV is more pronounced in HBV-A than

HBV-D. A higher production of HBsAg by HBV-D could diminish the competition

between HBV and HDV for HBsAg, allowing a more efficient HBV encapsidation.[44]

The clinical impact of infection with distinct HBV genotypes in patients with

delta virus superinfection has not yet been examined and warrants further

investigation.

[Guest guest]

http://www.medscape.com/viewarticle/580606?src=mp & spon=20 & uac=31238BR

4th International HIV and Hepatitis Co-infection Workshop

Selection from: The 4th International HIV and Hepatitis Co-infection Workshop

Conference Summary

Introduction: 4th International HIV and Hepatitis Co-infection Workshop

More than 400 hepatologists and infectious diseases specialists attended this

year's Co-infection Workshop, which was held in Madrid at the beginning of the

summer. Many of the top leaders in the field participated in the meeting and

discussed the most challenging aspects and controversies in the field of

coinfection with HIV and hepatitis viruses.

Delta Hepatitis in HIV Patients

Around 10% to 15% of chronic HBV carriers are seropositive for delta antibodies,

regardless of HIV infection. The majority of HDV-Ab+ individuals are viremic for

delta virus[42] and therefore are actively superinfected, showing a more rapid

progression of liver disease. Patients with HIV infection show higher viral load

levels of HDV than their HIV-negative patients. Heiner Wedemeyer[43] (Hannover

Medical School, Hannover, Germany) discussed the course of delta hepatitis,

stressing its epidemiology in HIV-infected individuals and the potential impact

of wide and prolonged use of anti-HBV medications in this population. Spanish

researchers showed that by sustained suppression of HBV replication,

long-lasting treatment with anti-HBV antiretroviral drugs may provide an

indirect inhibitory effect on HDV replication.[42]

Delta virus requires the replication of HBV to propagate. Little is know about

its behavior in patients harboring distinct HBV genotypes. Spanish researchers

found that the inhibitory effect of HDV on HBV is more pronounced in HBV-A than

HBV-D. A higher production of HBsAg by HBV-D could diminish the competition

between HBV and HDV for HBsAg, allowing a more efficient HBV encapsidation.[44]

The clinical impact of infection with distinct HBV genotypes in patients with

delta virus superinfection has not yet been examined and warrants further

investigation.

[Guest guest]

http://www.medscape.com/viewarticle/580606?src=mp & spon=20 & uac=31238BR

4th International HIV and Hepatitis Co-infection Workshop

Selection from: The 4th International HIV and Hepatitis Co-infection Workshop

Conference Summary

Introduction: 4th International HIV and Hepatitis Co-infection Workshop

More than 400 hepatologists and infectious diseases specialists attended this

year's Co-infection Workshop, which was held in Madrid at the beginning of the

summer. Many of the top leaders in the field participated in the meeting and

discussed the most challenging aspects and controversies in the field of

coinfection with HIV and hepatitis viruses.

Delta Hepatitis in HIV Patients

Around 10% to 15% of chronic HBV carriers are seropositive for delta antibodies,

regardless of HIV infection. The majority of HDV-Ab+ individuals are viremic for

delta virus[42] and therefore are actively superinfected, showing a more rapid

progression of liver disease. Patients with HIV infection show higher viral load

levels of HDV than their HIV-negative patients. Heiner Wedemeyer[43] (Hannover

Medical School, Hannover, Germany) discussed the course of delta hepatitis,

stressing its epidemiology in HIV-infected individuals and the potential impact

of wide and prolonged use of anti-HBV medications in this population. Spanish

researchers showed that by sustained suppression of HBV replication,

long-lasting treatment with anti-HBV antiretroviral drugs may provide an

indirect inhibitory effect on HDV replication.[42]

Delta virus requires the replication of HBV to propagate. Little is know about

its behavior in patients harboring distinct HBV genotypes. Spanish researchers

found that the inhibitory effect of HDV on HBV is more pronounced in HBV-A than

HBV-D. A higher production of HBsAg by HBV-D could diminish the competition

between HBV and HDV for HBsAg, allowing a more efficient HBV encapsidation.[44]

The clinical impact of infection with distinct HBV genotypes in patients with

delta virus superinfection has not yet been examined and warrants further

investigation.